Novo Holdings co-leads Swiss funding round

HBM Partners and Novo Holdings have joined forces to co-lead a CHF 100m investment round in biotech firm Numab which is developing a cancer treatment that will compete with one of Genmab's projects.

Nanna Lüneborg Partner at Novo Ventures. | Photo: Novo Ventures

Swiss biotech company Numab has received a capital injection for the further development of its main candidate for treating a series of cancer diseases.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs